English, Article edition: The Economic Value of a New Insulin Preparation, Humalog(R) Mix 25(TM): Measured by a Willingness-To-Pay Approach George Dranitsaris; Christopher J. Longo; Loren D. Grossman

User activity

Share to:
 
Bookmark: http://trove.nla.gov.au/version/118506
Physical Description
  • article
Language
  • English

Edition details

Title
  • The Economic Value of a New Insulin Preparation, Humalog(R) Mix 25(TM): Measured by a Willingness-To-Pay Approach
Author
  • George Dranitsaris
  • Christopher J. Longo
  • Loren D. Grossman
Physical Description
  • article
Notes
  • Objective: To measure the economic value of a new insulin formulation consisting of rapid-acting insulin lispro and intermediate-acting neutral protamine lispro in a 25 : 75 ratio (Humalog(R) Mix 25(TM)). Design and Setting: A cost-benefit analysis using a consumer-based willingness-to-pay (WTP) approach was used. The study sample consisted of 80 Canadian taxpayers randomly selected from Ontario and Quebec. After background information on the differences between Humalog(R) Mix 25(TM) and human 30/​70 insulin were presented, respondents were asked what their preferred product would be if they were diagnosed with diabetes mellitus. Respondents were then asked the maximum premium that they would pay per month in the form of a user's fee for the insulin of their choice. Study Perspective: Canadian taxpayer perspective. Main Outcome Measures and Results: The WTP survey instrument was simple to administer and easily understood by participants. Approximately 84% of the sample of taxpayers preferred to use Humalog(R) Mix 25(TM) rather than human 30/​70 insulin and were willing to pay for it (p =​ 0.012). They were willing to pay a mean of $Can35.28 [95% confidence interval (CI): $Can27.50 to $Can43.07] per month for the benefits offered by Humalog(R) Mix 25(TM), which was at least 2-fold higher than the incremental monthly cost of the drug (1999 values). Conclusions: The results of the study revealed that Canadians prefer to use Humalog(R) Mix 25(TM) instead of human 30/​70 insulin, and they would be willing to pay for it. Compared with other drugs, this overall net gain suggests that Humalog(R) Mix 25(TM) represents good value for money and should be considered for reimbursement by government formularies and other third-party payers.
  • Antihyperglycaemics, Cost benefit, Insulin lispro, Pharmacoeconomics, Type 1 diabetes mellitus, Type 2 diabetes mellitus, Willingness to pay
  • RePEc:wkh:phecon:v:18:y:2000:i:3:p:275-287
Language
  • English
Contributed by
OAIster

Get this edition

  • Set up My libraries

    How do I set up "My libraries"?

    In order to set up a list of libraries that you have access to, you must first login or sign up. Then set up a personal list of libraries from your profile page by clicking on your user name at the top right of any screen.

  • All (1)
  • Unknown (1)
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.
None of your libraries hold this item.

User activity


e.g. test cricket, Perth (WA), "Parkes, Henry"

Separate different tags with a comma. To include a comma in your tag, surround the tag with double quotes.

Be the first to add a tag for this edition

Be the first to add this to a list

Comments and reviews

What are comments? Add a comment

No user comments or reviews for this version

Add a comment